Patent ID: 11885796
Assignee: LDN PHARMA LIMITED
Field: Measurement (Instruments)
Classification: CPC G  A | IPC A  G

Claim 0:
1. An in vitro method for identifying an anti-cancer agent, the therapeutic efficacy of which is enhanced upon administration with a second agent that increases the expression of opioid receptor kappa-1 (OPRK1), comprising the steps of:
a) co-incubating a population of cells with a target anti-cancer agent and said second agent; and
b) measuring the cytotoxicity and/or cytostasis in the population of cells;
wherein the therapeutic efficacy of the target anti-cancer agent is enhanced if the cytotoxicity and/or cytostasis of the target anti-cancer agent is increased compared to a control, and
wherein the second agent is 6-β-naltrexol or a pharmaceutically acceptable salt thereof and is provided in an amount sufficient to increase the concentration of OPRK1 by at least 10% above the normal basal levels expected in the population of cells.